Teva Pharmaceutical Industries Limited (TEVA) Holdings Lifted by Point View Wealth Management Inc.

Point View Wealth Management Inc. boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 56.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,375 shares of the company’s stock after buying an additional 24,969 shares during the period. Point View Wealth Management Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $1,221,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Security National Bank of Sioux City Iowa IA grew its holdings in shares of Teva Pharmaceutical Industries Limited by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Teva Pharmaceutical Industries Limited by 0.3% during the 2nd quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock worth $2,177,000 after purchasing an additional 178 shares in the last quarter. Managed Account Services Inc. grew its holdings in shares of Teva Pharmaceutical Industries Limited by 1.4% during the 2nd quarter. Managed Account Services Inc. now owns 14,911 shares of the company’s stock worth $495,000 after purchasing an additional 211 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited by 3.6% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after purchasing an additional 294 shares in the last quarter. 52.29% of the stock is currently owned by institutional investors.

Several brokerages have recently weighed in on TEVA. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and decreased their price target for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. lowered Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 price target on the stock. in a research note on Thursday, August 3rd. Seven analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and a consensus target price of $21.88.

ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/20/teva-pharmaceutical-industries-limited-teva-holdings-lifted-by-point-view-wealth-management-inc.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.85 during midday trading on Monday, reaching $12.99. The company had a trading volume of 15,244,933 shares, compared to its average volume of 26,260,000. The company has a market capitalization of $12,010.00, a P/E ratio of 3.20 and a beta of 0.52. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.85 and a fifty-two week high of $39.08.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.62%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -16.01%.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit